Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: A prospective, two-stage study

The Lancet Oncology

Volumn 13, Issue 11, 2012, Pages 1114-1124

  Olmos, David ^a,b,c   Brewer, Daniel ^b   Clark, Jeremy ^b   Danila, Daniel C ^d,f   Parker, Chris ^a   Attard, Gerhardt ^a,b   Fleisher, Martin ^e   Reid, Alison H M ^a,b   Castro, Elena ^a,b   Sandhu, Shahneen K ^a,b   Barwell, Lorraine ^g   Oommen, Nikhil Babu ^a   Carreira, Suzanne ^b   Drake, Charles G ^h   Jones, Robert ⁱ   Cooper, Colin S ^b   Scher, Howard I ^d,f   de Bono, Johann S ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d Sidney Kimmel Center for Prostate and Urologic Cancers   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; GENE EXPRESSION; HUMAN; LATENT PROCESS DECOMPOSITION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; METASTASIS; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CODING; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; CASTRATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868202120     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70372-8     Document Type: Article

References (38)

1. Albertsen PC Treatment of localized prostate cancer: when is active surveillance appropriate?. Nat Rev Clin Oncol 2010, 7:394-400.
2. Ang JE, Olmos D, de Bono JS CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009, 100:671-675.
3. Fiorentino M, Capizzi E, Loda M Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am 2010, 37:131-141.
4. Basu B, Olmos D, de Bono JS Targeting IGF-1R: throwing out the baby with the bathwater?. Br J Cancer 2011, 104:1-3.
5. Schwarzenbach H, Hoon DS, Pantel K Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11:426-437.
6. Fradet Y Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr Opin Urol 2009, 19:243-246.
7. Bickers B, Aukim-Hastie C New molecular biomarkers for the prognosis and management of prostate cancer-the post PSA era. Anticancer Res 2009, 29:3289-3298.
8. Olmos D, Arkenau HT, Ang JE, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009, 20:27-33.
9. Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009, 69:2912-2918.
10. Sotiriou C, Piccart MJ Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007, 7:545-553.
11. van't Veer LJ, Bernards R Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008, 452:564-570.
12. Shiozawa Y, Pedersen EA, Havens AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011, 121:1298-1312.
13. Shiozawa Y, Pienta KJ, Taichman RS Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 2011, 17:5553-5558.
14. Ozen M, Hopwood VL, Johnston DA, et al. Aneuploidy index in blood: a potential marker for early onset, androgen response, and metastasis in human prostate cancer. Urology 1999, 53:381-385.
15. Toncheva D, Nacheva M Chromosomal instability in cancer patients. Hum Genet 1998, 103:367-371.
16. Dotan ZA, Dotan A, Ramon J, Avivi L Altered mode of allelic replication accompanied by aneuploidy in peripheral blood lymphocytes of prostate cancer patients. Int J Cancer 2004, 111:60-66.
17. Dotan ZA, Dotan A, Ramon J, Avivi L Aberrant allele-specific replication, independent of parental origin, in blood cells of cancer patients. BMC Cancer 2008, 8:390.
18. Rainen L, Oelmueller U, Jurgensen S, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 2002, 48:1883-1890.
19. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072. the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
20. Gail M, Gart JJ The determination of sample sizes for use with the exact conditional test in 2 × 2 comparative trials. Biometrics 1973, 29:441-448.
21. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001, 29:365-371.
22. Rogers S, Girolami M, Campbell C, Breitling R The latent process decomposition of cDNA microarray data sets. IEEE/ACM Trans Comput Biol Bioinformatics 2005, 2:143-156.
23. Breiman L Random forests. Mach Learn 2001, 45:5-32.
24. Clipsham RC, McCabe ER Single-tube gene-specific expression analysis by high primer density multiplex reverse transcription. Mol Genet Metab 2001, 74:435-448.
25. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26:2667-2673.
26. Janes H, Pepe MS, Gu W Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 2008, 149:751-760.
27. Ware JH The limitations of risk factors as prognostic tools. N Engl J Med 2006, 355:2615-2617.
28. Kono M, Kondo T, Takagi Y, Wada A, Fujimoto K Morphological definition of CD71 positive reticulocytes by various staining techniques and electron microscopy compared to reticulocytes detected by an automated hematology analyzer. Clin Chim Acta 2009, 404:105-110.
29. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006, 177:7398-7405.
30. Valdman A, Jaraj SJ, Compérat E, et al. Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue. APMIS 2010, 118:360-365.
31. Ross RW, Galsky MD, Scher HI, et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol 2012, published online Oct 8. http://dx.doi.org/10.1016/S1470-2045(12)70263-2.
32. Zhao L, Lee BY, Brown DA, et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 2009, 69:7696-7703.
33. Showe MK, Vachani A, Kossenkov AV, et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 2009, 69:9202-9210.
34. Hausen P, Stein H On the synthesis of RNA in lymphocytes stimulated by phytohemagglutinin. 1. Induction of uridine-kinase and the conversion of uridine to UTP. Eur J Biochem 1968, 4:401-406.
35. Aarøe J, Lindahl T, Dumeaux V, et al. Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res 2010, 12:R7.
36. Kennedy L, Vass JK, Haggart DR, et al. Hematopoietic lineage transcriptome stability and representation in PAXgene collected peripheral blood utilising SPIA single-stranded cDNA probes for microarray. Biomark Insights 2008, 3:403-417.
37. Calin GA, Croce CM MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
38. Chiam K, Ricciardelli C, Bianco-Miotto T Epigenetic biomarkers in prostate cancer: current and future uses. Cancer Lett 2012, published online March 3. http://dx.doi.org/10.1016/j.canlet.2012.02.011.